27 January 2021

Eli Lilly announced that its neutralising antibodies bamlanivimab and etesevimab together helped in reducing the risk of Covid-19 hospitalisations and deaths, which are referred to as events, by 70% in its Phase III BLAZE-1 trial. Among 1,035 patients, there were 11 events in patients taking therapy and 36 of these events in patients taking placebo. The trial also had only 10 deaths in total, all of which occurred in the placebo group.

Care Access Research, a decentralised research organisation, and AstraZeneca have announced a collaboration to fast-track a Phase III clinical trial for AZD7442, AstraZeneca’s long-acting monoclonal antibody combination, in the US to prevent Covid-19 . The STORM CHASER trial assesses the safety and efficacy of AZD7442 for post-exposure prophylaxis and preventive treatment among 1,125 participants in the US and UK.

Shionogi and BioAge announced a license agreement that gives the latter exclusive rights to develop and market BGE-175, a prostaglandin D2 DP1 receptor antagonist, to control the severity of Covid-19 in the US and Europe. BGE-175 was discovered by Shionogi and was previously in its development stage for treating allergic rhinitis.

Foreign Minister Mohammad Javad Zarif announced that Iran has approved Russia’s Sputnik V coronavirus vaccine. Iran stated that it will only depend on vaccines developed by Russia, China, or India, while also working towards producing its own shot.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.